CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present or host one-on-one meetings at five upcoming Investor Conferences.

29th Annual Piper Jaffray Healthcare ConferenceDate: Wednesday, November 29, 2017Fireside Chat: 1:00-1:25 PM ET

Barclays Gene Editing & Gene Therapy SummitDate: Thursday, November 30, 2017Presentation: 3:00-3:20 PM ETPanel Discussion: 3:40-4:40 PM ET Gene Editing: Putting Molecular Scissors in Real Life Use

Evercore ISI BioPharma Catalyst/Deep Dive ConferenceDate: Thursday, November 30, 2017 Fireside Chat: 10:15-10:35 AM ET

Citi 2017 Global Healthcare ConferenceDate: Wednesday December 6, 2017One-on-one meetings only

Guggenheim 4th Annual Boston Healthcare ConferenceDate: Tuesday December 13, 2017One-on-one meetings only

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

MEDIA CONTACTS:Jennifer PaganelliWCG on behalf of CRISPR+1 347-658-8290 [email protected]

INVESTOR CONTACT:Chris Erdman+1 617.307.7227 [email protected]

Chris BrinzeyWestwicke Partners for CRISPR+1 339-970-2843 [email protected]

Source: CRISPR Therapeutics AG

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
• Citi cuts TJX Companies rating to Neutral, lowers price target
• Mayfield Adds Aditya Singh as Partner to Expand AI Infrastructure Investing at Inception